Journal
ANNALS OF GASTROENTEROLOGICAL SURGERY
Volume 2, Issue 2, Pages 116-123Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/ags3.12060
Keywords
gastric cancer; HIPEC; intraperitoneal chemotherapy; peritoneal metastasis
Categories
Funding
- Japan Agency for Medical Research and Development [17KI0201053 h0002]
- Japan Society for the Promotion of Science [17H04286]
- Grants-in-Aid for Scientific Research [17H04286] Funding Source: KAKEN
Ask authors/readers for more resources
Despite recent advances in chemotherapy, outcomes of patients with peritoneal metastases (PM) from gastric cancer are still very poor and standard treatment has not been established. Although oral S-1 appears to be effective for patients with PM, the effects of systemic chemotherapy are limited. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) yield fewer benefits in patients with PM from gastric cancer than in patients with PM from other malignancies. In comparison, repeated intraperitoneal chemotherapy (RIPEC) with taxanes using an implantable peritoneal access port has a pharmacokinetic advantage for the control of peritoneal lesions and in combination with systemic chemotherapy can result in surprisingly long-term survival in patients with PM from gastric cancer. Herein, we review the results of recent clinical studies specifically targeting PM from gastric cancer and discuss future prospects for an intraperitoneal approach to the ideal treatment of patients with gastric cancer with peritoneal involvement.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available